Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.


BACKGROUND Sunitinib is a potent oral tyrosine kinase inhibitor of VEGFRs, KIT, and PDGFRs. In a single arm phase II trial, sunitinib has demonstrated its potential activity in refractory thymic carcinoma (TC) and thymoma (T). Taking advantage of the French RYTHMIC network prospective database, we investigated the off-label efficacy of sunitinib in… (More)
DOI: 10.1016/j.lungcan.2016.04.024


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics